复星医药投资爱美津制药

新闻资讯 News

2015年1月9日

及时发布，请联系：
美国: (732) 993-9821
中国: +86-512-6745-1085 分机 101
info@amerigenpharma.com

美国新泽西州林德赫斯特，2015年1月9日消息，爱美津制药有限公司（“爱美津”）今天宣布与复星医药（“复星”）分公司签署协议，复星将向爱美津投资3500万美元新发行的股权。爱美津将借此主要通过对产品开发和业务发展的额外投资来深化其产品线。由于其投资，复星也将获得爱美津董事会席位。 爱美津总裁兼首席执行官John Lowry先生在谈到这一合作时表示：“我很高兴并欢迎复星能成为爱美津的投资者。鉴于复星在中国医疗保健行业的领先地位及其国际发展前景，我们认为这种股权投资是两家公司更广泛合作的第一步，将促进联合开发针对美国和中国市场的药产品”。复星医药董事长陈启余先生补充说：“从金融和战略的角度来看，我们很高兴与爱美津达成这一协议。 爱美津通过其在苏州的通过美国FDA和中国CFDA审核的工厂，在中国建立了一个令人印象深刻的平台，加上有吸引人的产品线和在美国的商业存在，爱美津是复星医药的理想合作伙伴。”

Lyndhurst NJ, USA, January 9, 2015 – Amerigen Pharmaceuticals Limited (“Amerigen”) today announced the signing of an agreement with an affiliate of Fosun Pharma (“Fosun”) under which Fosun will invest USD 35 million in newly issued equity in Amerigen. Amerigen intends to use the proceeds primarily to deepen its product pipeline through additional investments in product development and business development. As a result of its investment, Fosun will also be entitled to a seat on Amerigen’s board of directors. Commenting on the deal, John Lowry, Amerigen’s President and CEO, stated “I am delighted to welcome Fosun as an investor in Amerigen. With Fosun’s leading presence across the spectrum of healthcare in China, and its international outlook, we view this equity investment as the first step in a broader collaboration between the two companies that will facilitate the joint development of products targeting both the United States and Chinese pharmaceutical markets. ” Mr. Chen Qiyu, Fosun Pharma’s Chairman added “From both financial and strategic viewpoints, we are excited to enter into this agreement with Amerigen. Through its US FDA and CFDA approved facility in Suzhou, Amerigen has established an impressive platform in China which, when coupled with an attractive product portfolio and a commercial presence in the United States, makes Amerigen an ideal partner for Fosun Pharma.”

关于爱美津 About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

爱美津制药致力于仿制药所涉及到的全部阶段的业务，是一家包括美国和中国多成员企业的集团公司。集团由爱美津制药控股。美国市场的注册和商业活动由位于新泽西州，林赫斯特的美国爱美津负责；集团的中国分公司，苏州爱美津制药有限公司，位于中国江苏省苏州市。爱美津制药集团目前在美国以及中国均有药品上市和销售，同时，我们拥有活跃的在研产品组，面向美国食品药品监督管理局（FDA）注册和已申报若干个仿制药品种（ANDA），并且计划开展向中国食品药品监督管理局（CFDA）注册和申报产品的工作。爱美津从事开发的口服制剂产品，是开发难度高，需要专门的技术，或生产要求高度严格管理控制，以及法规复杂，需要规避或挑战专利的仿制药。爱美津集团旗下公司或合作方开发和生产的所有产品，都满足高质量标准，包括美国FDA。